eligibility_summary
Adults (≥18) with recurrent/metastatic solid tumors (confirmed), ECOG 0–4 (3–4 only with tumor burden), failed/intolerant/refuse standard therapy, ≥1 RECIST 1.1 measurable lesion, life expectancy ≥3 months, and sample for genomics (FFPE/≥200 mL malignant effusion/excised LN/~5 mL blood), consent required. Exclude: in other treatment trials, serious/uncontrolled comorbidities, pregnant/lactating, fertile without contraception.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Pan-cancer, MTB-guided basket trial matching therapies to tumor genomics. Drugs and mechanisms: olaparib (small-molecule PARP1/2 inhibitor, DNA-repair synthetic lethality), temozolomide (alkylating chemo), anlotinib, lenvatinib, pazopanib (multi-TKIs of VEGFR/FGFR/PDGFR/KIT, anti-angiogenic), trametinib (MEK1/2 inhibitor), dabrafenib (BRAF V600 inhibitor), vebreltinib (MET TKI), alpelisib (PI3Kα inhibitor), palbociclib (CDK4/6 inhibitor), chidamide (HDAC inhibitor, epigenetic/immunomodulatory), sacituzumab govitecan-hziy (TROP-2–directed ADC delivering SN-38), PD-1/PD-L1 ± CTLA-4 inhibitors (checkpoint mAbs). Targeted cells/pathways: MAPK (KRAS/BRAF/MEK), PI3K/AKT/mTOR, MET, angiogenesis/VEGFR (tumor endothelium/TME), cell-cycle RB (CCND1/11q13), DNA repair (BRCA/HRD), TOP1 via ADC payload, epigenetic/immune modulation, T cells (PD-1/PD-L1, CTLA-4). Cohorts include dMMR/MSI-H/TMB-H, NTRK/RET fusions, BRAF V600E, KRAS G12C, HER2 3+, METex14/amplification, TP53, MAP2K1.